NCT05419726Recruiting
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Source: ClinicalTrials.gov · Last updated 11 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Their activities include increasing insulin production by pancreatic beta cells, improving insulin sensitivity in muscles and weight loss. The mechanisms underpinning the weight loss caused by GLP-1 agonists have not yet been fully elucidated, but brown adipose tissue (BAT) appears to play an important role. We propose to assess BAT activity, using infrared thermography camera images, before individuals start weekly administration of semaglutide, at week 2-4, and week 18-20. We hypothesize that this GLP-1 agonist, semaglutide, will cause an increase in BAT activity and a corresponding increase in basal metabolic rate.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 10 Jun 2022
- Start date
- 1 Feb 2023
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- University of California, Los Angeles
- Diseases
- Obesity
- NCT number
- NCT05419726
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Feb 2023 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- History of prior neck surgery and /or neck irradiation
- Use of beta blocker agents
- Use of any other glucose lowering medication
- History of neuropathic disorders (e.g. diabetic neuropathy)
- Diabetic patients
- Individuals without normal thyroid function
- Individuals with cancer
- Any significant chronic disease or renal, hepatic or endocrine disease
- Current smokers
- Inability of patient to provide consent either for medical reasons or psychiatric reasons
Who the study is looking for
- Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
- \>18 years of age and willing to participate
- Male or post-menopausal females
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA Health Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.